Angiotensin Receptor–Neprilysin Inhibition in Acute Myocardial Infarction | Zendy

Marc A. Pfeffer | Zendy; Brian Claggett | Zendy; Eldrin F. Lewis | Zendy; Christopher B. Granger | Zendy; Lars Køber | Zendy; Aldo P. Maggioni | Zendy; Douglas L. Mann | Zendy; John J.V. McMurray | Zendy; JeanLucien Rouleau | Zendy; Scott D. Solomon | Zendy; Philippe Gabríel Steg | Zendy; Otávio Berwanger | Zendy; Maja Čikeš | Zendy; Carmine G. De Pasquale | Zendy; Cara East | Zendy; Alberto Fernández | Zendy; Karola Jering | Zendy; Ulf Landmesser | Zendy; Roxana Mehran | Zendy; Béla Merkely | Zendy; Freny Vaghaiwalla Mody | Zendy; Mark C. Petrie | Zendy; Ivo Petrov | Zendy; Morten Schou | Zendy; Michele Senni | Zendy; David Sim | Zendy; Peter van der Meer | Zendy; Martin Lefkowitz | Zendy; Yig Zhou | Zendy; Jianjian Gong | Zendy; Eugene Braunwald | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Angiotensin Receptor–Neprilysin Inhibition in Acute Myocardial Infarction

Author(s) -

Marc A. Pfeffer,

Brian Claggett,

Eldrin F. Lewis,

Christopher B. Granger,

Lars Køber,

Aldo P. Maggioni,

Douglas L. Mann,

John J.V. McMurray,

JeanLucien Rouleau,

Scott D. Solomon,

Philippe Gabríel Steg,

Otávio Berwanger,

Maja Čikeš,

Carmine G. De Pasquale,

Cara East,

Alberto Fernández,

Karola Jering,

Ulf Landmesser,

Roxana Mehran,

Béla Merkely,

Freny Vaghaiwalla Mody,

Mark C. Petrie,

Ivo Petrov,

Morten Schou,

Michele Senni,

David Sim,

Peter van der Meer,

Martin Lefkowitz,

Yig Zhou,

Jianjian Gong,

Eugene Braunwald

Publication year - 2021

Publication title -

new england journal of medicine

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2104508

Subject(s) - neprilysin , myocardial infarction , valsartan , medicine , cardiology , heart failure , sacubitril , angiotensin converting enzyme , ace inhibitor , angiotensin receptor , angiotensin ii , receptor , enzyme , blood pressure , biochemistry , chemistry

In patients with symptomatic heart failure, sacubitril-valsartan has been found to reduce the risk of hospitalization and death from cardiovascular causes more effectively than an angiotensin-converting-enzyme inhibitor. Trials comparing the effects of these drugs in patients with acute myocardial infarction have been lacking.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research